Effect of irbesartan on angiotensin II-induced adiponectin expression in human cardiomyocytes

Acta Cardiologica Sinica

Volumn 27, Issue 4, 2011, Pages 244-251

  Yin, Wei Hsian ^a,c   Chen, Jaw Wen ^b,c   Lin, Shing Jong ^b,c   Young, Mason Shing ^a  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Angiotensin II; Angiotensin receptor blocker; Cardiomyocytes

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADIPONECTIN; ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

EID: 84863015675     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Dzau VJ. Theodore cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52. (Pubitemid 32304002)
2. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79. (Pubitemid 38249147)
3. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007;93:903-7. (Pubitemid 47122034)
4. KimYS, Greenberg B. Update on renin-angiotensin-aldosterone blockade in heart failure. Curr Treat Options Cardiovasc Med 2009;11:455-66.
5. Verma A, Bulwer B, Dhawan I, et al. Aldosterone receptor antagonist and heart failure following acute myocardial infarction. Acta Cardiol Sin 2010;26:203-15.
6. Diez J. Profibrotic effects of angiotensin II in the heart: a matter of mediators. Hypertension 2004;43:1164-5. (Pubitemid 38691732)
7. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009;6:27-35.
8. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005;11:1096-103. (Pubitemid 41486832)
9. Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007;115:1408-16. (Pubitemid 46648376)
10. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004;10:1384-9. (Pubitemid 40022722)
11. Fujita K, Maeda N, Sonoda M, et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-α. Arterioscler Thromb Vasc Biol 2008;28:863-70. (Pubitemid 351544100)
12. Schram K, Sweeney G. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med 2008;18:199-205.
13. Brochu-Gaudreau K, Rehfeldt C, Blouin R, et al. Adiponectin action from head to toe. Endocrine 2010;37:11-32.
14. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam study. Eur Heart J 2001;22:1318-27. (Pubitemid 32737624)
15. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62. (Pubitemid 41372115)
16. Tamura T, Furukawa Y, Taniguchi R, et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007;71:623-30. (Pubitemid 46683348)
17. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723-30. (Pubitemid 47227093)
18. Anker SD, Ponikowski P, Varney S, et al.Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3. (Pubitemid 27158249)
19. Takahashi T, Saegusa S, Sumino H, et al. Adiponectin, T-cadherin and tumor necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. J Int Med Res 2005;33:236-44. (Pubitemid 40372440)
20. Takano H, Obata JE, Kodama Y, et al. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol 2009;132:221-6.
21. Piñeiro R, Iglesias MJ, Gallego R, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 2005;579:5163-9. (Pubitemid 41318086)
22. Skurk C, Wittchen F, Suckau L, et al. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 2008;29:1168-80. (Pubitemid 351844892)
23. Hattori Y, Akimoto K, Gross SS, et al. Angiotensin-II-induced oxidative stress elicits hypoadiponectinemia in rats. Diabetologia 2005;48:1066-74. (Pubitemid 40909640)
24. Kurata A, Nishizawa H, Kihara S, et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocyhtokine dysregulation. Kidney Int 2006;70:1717-24. (Pubitemid 44684802)
25. Suzuki H, Eguchi S. Adiponectin versus angiogensin II: key pathological role of their misbalance. Kidney Int 2006;70:1678-9. (Pubitemid 44684797)
26. Xu D, Fang C, SuW, et al. Protective effect of tongxinluo on oxidative injury induced by angiotensin II in rats. Acta Cardiol Sin 2011;27:189-96.
27. Shinohara T, Takahashi N, Abe I, et al. Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance. Obes Res Clin Pract; http://dx.doi.org/10.1016/j.orcp.2011.03.011.
28. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006;29:957-61. (Pubitemid 46344228)
29. Koh KK, Quon MJ, Han SH, et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006;108:96-100. (Pubitemid 43324913)
30. Araújo JP, Lourenço P, Rocha-Gonçalves F, et al. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009;11:567-72.
31. Yamaji M, Tsutamoto T, Tanaka T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 2009;73:1067-73.
32. Saegusa S, Fei Y, Takahashi T, et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther 2007;21:155-60. (Pubitemid 46817480)
33. Yu F, Chen R, Takahashi T, et al. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int J Cardiol 2008;129:414-21.
34. Ho YL, Lin YH, Lee CM, et al. Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide. Clin Biochem 2009;42:1407-12.
35. Natarajan R, Salloum FN, Fisher BJ, et al. Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol 2008;51:178-87. (Pubitemid 351301479)
36. Date H, Imamura T, Ideguchi T, et al. Adiponectin produced in coronary circulation regulates coronary flow reserve in nondiabetic patients with angiographically normal coronary arteries. Clin Cardiol 2006;29:211-4.
37. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61. (Pubitemid 40385531)
38. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005;25:2062-8. (Pubitemid 41416301)
39. Yin WH, Chen YH, Wei J, et al. Associations between endothelin-1 and adiponectin in chronic heart failure. Cardiology 2011;118:207-16.
40. nd ed. New York: Springer Science+Business Media, 2010:3-38.